MONTREAL, - Merck announced today that VICTRELIS™ (boceprevir) has been approved in Canada for the treatment of chronic hepatitis C (CHC) genotype 1 infection in combination with the current standard therapy, peginterferon alpha and ribavirin (peg/riba), in adult patients (18 years and older) with compensated liver disease, including cirrhosis, who are previously untreated or who have failed previous therapy.1